Medivir AB announces that the company’s patent application, covering both substance claims for fostroxacitabine bralpamide and its use for liver cancer treatment, has recently been approved by the Chinese patent authority.
Medivir AB announces that the company’s patent application, covering both substance claims for fostroxacitabine bralpamide and its use for liver cancer treatment, has recently been approved by the Chinese patent authority.